Table 5.

Clinical activity of selected vascular endothelia growth factor-targeted agents in advanced renal cell carcinoma

Reference	Agent	No	Trial design	Prior Therapy	Overall response rate
Yang et al	Bevacizumab	116	Randomized phase II high-dose bevacizumab versus low dose bevacizumab versus placbo	Cytokines	10% vs 0%
Motzer et al	Sunitinib	63, 106	Single-arm phase II single agent sunitinib	Cytokines	40%,34%
Motzer et al	Sunitinib	750	Randomized phase III sunitinib versus IFN-a	None	31 vs 6%
Escudier et al	Sorafenib	903	Randomized phase III sorafenib versus placebo	Various	2% vs 0%
Hudes G et al	Temsirolimus	626	Randomized phase III temsirolimus versus IFN-a versus temsirolimus+IFN-a	None	9% vs 7% vs 11%